New Peptide Drug VS-214 Aims to Restore Blood Flow and Prevent Amputations in PAD Patients
Vasa Therapeutics advances VS-214, a peptide targeting poor limb circulation, toward first human trials in 2026 — addressing a massively underserved condition.
Summary
Peripheral artery disease (PAD) affects 10–12 million Americans and causes around 400 limb amputations daily. Vasa Therapeutics is developing VS-214, a synthetic peptide that mimics a natural molecule called apelin, to stimulate new blood vessel growth, improve blood flow to the legs, and restore muscle function. The drug is designed for patients who already have symptoms — pain, weakness, poor healing — and currently have few effective drug options. The company presented early research at a major American Heart Association conference in May 2026 and is targeting a first-in-human clinical trial later this year. If successful in trials, VS-214 could represent a meaningful advance for a condition closely tied to cardiovascular aging and risk of disability.
Detailed Summary
Peripheral artery disease is one of the most common and underappreciated consequences of cardiovascular aging. Caused by the buildup of plaque in arteries that supply the legs and feet, PAD restricts blood flow, impairs mobility, causes chronic pain, and in severe cases leads to amputation. With an estimated 10 to 12 million Americans affected and roughly 400 non-traumatic amputations occurring every day in the US, the condition represents a significant unmet medical need — particularly as the population ages.
Vasa Therapeutics is developing VS-214, a long-acting peptide analog of apelin, a naturally occurring signaling molecule involved in vascular function. The drug is designed to promote neovascularization — the growth of new blood vessels — in ischemic tissue, thereby improving perfusion to the limbs and restoring muscle endurance. This mechanism targets the root cause of PAD symptoms rather than just managing pain or risk factors.
The company presented an abstract on VS-214 at the American Heart Association's Vascular Discovery: From Genes to Medicine Scientific Sessions in Bellevue, Washington, in May 2026. The oral presentation, delivered by CEO Artur Plonowski, MD, PhD, marks a significant visibility milestone for the program. Vasa reports it is advancing toward a first-in-human study within 2026, suggesting preclinical data have been sufficient to support regulatory clearance for early trials.
For longevity-focused readers, PAD is a strong marker of systemic vascular aging. People with PAD have dramatically elevated risks of heart attack, stroke, and reduced healthspan. Therapies that restore microvascular function could have broad implications beyond the legs — touching on muscle preservation, mobility, and metabolic health in older adults.
Caveats are important here. VS-214 has not yet been tested in humans, and efficacy and safety data from clinical trials are absent. This is an early-stage program and results in humans may not replicate preclinical findings. Investors and patients should monitor Phase 1 trial outcomes carefully before drawing conclusions.
Key Findings
- VS-214 is a peptide apelin analog designed to grow new blood vessels and restore limb blood flow in PAD patients.
- PAD affects 10–12 million Americans and causes approximately 400 non-traumatic amputations per day in the US.
- Vasa Therapeutics is targeting a first-in-human clinical trial for VS-214 in 2026, following positive preclinical data.
- PAD is a strong biomarker of systemic vascular aging, linking directly to cardiovascular disease risk and reduced healthspan.
- No pharmacological treatments currently address neovascularization in PAD, representing a significant therapeutic gap.
Methodology
This is a news report based on a company press release and conference abstract announcement. The source, Longevity.Technology, is a credible longevity-focused outlet, but the evidence base here is corporate communications rather than peer-reviewed data. No clinical trial results have been published yet.
Study Limitations
No human trial data exist yet; all efficacy claims are based on preclinical research not publicly detailed in this article. The article is derived from a company press release, introducing potential promotional bias. Independent peer-reviewed publication of VS-214 data should be sought before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.